112.27
-0.08(-0.07%)
Currency In USD
| Previous Close | 112.35 |
| Open | 111.72 |
| Day High | 113.03 |
| Day Low | 111.37 |
| 52-Week High | 122.2 |
| 52-Week Low | 45.91 |
| Volume | 228,112 |
| Average Volume | 753,433 |
| Market Cap | 7.49B |
| PE | -36.22 |
| EPS | -3.1 |
| Moving Average 50 Days | 106.88 |
| Moving Average 200 Days | 83.85 |
| Change | -0.08 |
If you invested $1000 in Rhythm Pharmaceuticals, Inc. (RYTM) since IPO date, it would be worth $4,569.39 as of December 25, 2025 at a share price of $112.27. Whereas If you bought $1000 worth of Rhythm Pharmaceuticals, Inc. (RYTM) shares 5 years ago, it would be worth $3,817.41 as of December 25, 2025 at a share price of $112.27.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
GlobeNewswire Inc.
Dec 11, 2025 12:30 PM GMT
-- BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy -- -- Promising results supportive of Phase 3, registrational trial
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
GlobeNewswire Inc.
Dec 10, 2025 9:01 PM GMT
BOSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025
GlobeNewswire Inc.
Nov 10, 2025 12:00 PM GMT
– Phase 3 TRANSCEND trial data showed setmelanotide achieved significant BMI reductions in patients with acquired hypothalamic obesity on concomitant treatment with GLP-1 therapy – – Analysis of data from Phase 3 TRANSCEND trial show clinically mean